Literature DB >> 24232046

Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer.

Steven J Nurkin, Hector R Nava, Sai Yendamuri, Charles M LeVea, Chumy E Nwogu, Adrienne Groman, Gregory Wilding, Andrew J Bain, Steven N Hochwald, Nikhil I Khushalani.   

Abstract

BACKGROUND: Endoscopic resection (ER) is an important advance in the management of esophageal tumors. It has been used successfully for superficial esophageal cancer and high-grade dysplasia (HGD) arising out of Barrett epithelium.
METHODS: From a single institution within the Department of Surgery, patients who underwent ER for esophageal tumors between December 2001 and January 2012 were evaluated. Demographic, clinical, and pathologic variables were collected and reviewed.
RESULTS: We identified 81 patients who underwent ER for esophageal lesions. Median patient age was 69 years, and the median follow-up was 3.25 years. In patients with HGD, at the time of last endoscopy, the complete eradication rate of HGD was 84 % and cancer-specific survival was 100 %. During surveillance, one patient developed an invasive carcinoma that required endoscopic therapy. Patients with T1a and negative deep margins on ER had a recurrence-free and cancer-specific survival of 100 %. There were seven patients with T1b and negative margins on ER. Three patients underwent esophagectomy; final pathology revealed no residual malignancy or lymph node metastasis. Two patients had definitive chemoradiation, and two patients were observed. To date, there has been no cancer recurrence. In all patients who underwent ER, there was one episode of bleeding that required endoscopic treatment and admission for observation.
CONCLUSIONS: ER can be performed safely and can adequately stage and often treat patients with HGD and superficial cancers. Patients with HGD and T1a disease with negative margins are cured with ER alone. Observation and surveillance may be an option for select patients with low-risk, early submucosal disease (T1b) and negative margins.

Entities:  

Mesh:

Year:  2014        PMID: 24232046     DOI: 10.1007/s00464-013-3270-3

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy.

Authors:  J J Nigro; J A Hagen; T R DeMeester; S R DeMeester; J H Peters; S Oberg; J Theisen; M Kiyabu; P F Crookes; C G Bremner
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

2.  Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.

Authors:  Boris Sepesi; Thomas J Watson; David Zhou; Marek Polomsky; Virginia R Litle; Carolyn E Jones; Daniel P Raymond; Rui Hu; Xing Qiu; Jeffrey H Peters
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

3.  Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions.

Authors:  H Inoue; K Takeshita; H Hori; Y Muraoka; H Yoneshima; M Endo
Journal:  Gastrointest Endosc       Date:  1993 Jan-Feb       Impact factor: 9.427

4.  Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.

Authors:  P K Nijhawan; K K Wang
Journal:  Gastrointest Endosc       Date:  2000-09       Impact factor: 9.427

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study.

Authors:  Femke P Peters; Mohammed A Kara; Wilda D Rosmolen; Fiebo J W ten Kate; Kausilia K Krishnadath; J Jan B van Lanschot; Paul Fockens; Jacques J G H M Bergman
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

7.  Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent.

Authors:  Hendrik Manner; Andrea May; Oliver Pech; Liebwin Gossner; Thomas Rabenstein; Erwin Günter; Michael Vieth; Manfred Stolte; Christian Ell
Journal:  Am J Gastroenterol       Date:  2008-09-10       Impact factor: 10.864

8.  Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.

Authors:  Jennifer Chennat; Vani J A Konda; Andrew S Ross; Alberto Herreros de Tejada; Amy Noffsinger; John Hart; Shang Lin; Mark K Ferguson; Mitchell C Posner; Irving Waxman
Journal:  Am J Gastroenterol       Date:  2009-08-18       Impact factor: 10.864

9.  Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.

Authors:  Hendrik Manner; Oliver Pech; Yvonne Heldmann; Andrea May; Juergen Pohl; Angelika Behrens; Liebwin Gossner; Manfred Stolte; Michael Vieth; Christian Ell
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

10.  Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.

Authors:  O Pech; A Behrens; A May; L Nachbar; L Gossner; T Rabenstein; H Manner; E Guenter; J Huijsmans; M Vieth; M Stolte; C Ell
Journal:  Gut       Date:  2008-05-06       Impact factor: 23.059

View more
  6 in total

Review 1.  Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Authors:  Magnus Halland; David Katzka; Prasad G Iyer
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

2.  Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.

Authors:  Mimi C Tan; Nabil Mansour; Donna L White; Amy Sisson; Hashem B El-Serag; Aaron P Thrift
Journal:  Aliment Pharmacol Ther       Date:  2020-05-26       Impact factor: 8.171

Review 3.  Potentially Curable Cancers of the Esophagus and Stomach.

Authors:  Elena Elimova; Dilsa Mizrak Kaya; Kazuto Harada; Jaffer A Ajani
Journal:  Mayo Clin Proc       Date:  2016-09       Impact factor: 7.616

4.  Endoscopic Ultrasound Stagingof Esophageal Cancer.

Authors:  Shyam Thakkar; Vivek Kaul
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

5.  MicroRNA-27a directly targets KRAS to inhibit cell proliferation in esophageal squamous cell carcinoma.

Authors:  Yuzhi Jiang; Yuting Duan; Haibin Zhou
Journal:  Oncol Lett       Date:  2014-11-11       Impact factor: 2.967

6.  The Relationship between Social Support and Quality of Life: Evidence from a Prospective Study in Chinese Patients with Esophageal Carcinoma.

Authors:  Yanjie Wang; Lili Zhu; Fang Yuan; Lixia Kang; Zhen Jia; Dongming Chen; Ping Zhang; Zhanchun Feng
Journal:  Iran J Public Health       Date:  2015-12       Impact factor: 1.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.